Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
GLP-1 receptor agonists
13 evidence topics · 10 sources
Semaglutide injection and tablets: FDA-approved indications
Semaglutide injection: dosage escalation and maintenance dosages for weight reduction, including 7.2 mg
Semaglutide tablets: administration on an empty stomach and maintenance dosage
Semaglutide injection and tablets: boxed warning for thyroid C-cell tumors
Semaglutide tablets: FDA approval for weight management in December 2025
Semaglutide 2.4 mg subcutaneous: cardiovascular outcomes in participants without diabetes in SELECT
“A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide 2.4 mg subcutaneous: two-year weight change in STEP 5
“The mean change in body weight from baseline to week 104 was −15.2% in the semaglutide group (n = 152) versus −2.6% with placebo (n = 152), for an estimated treatment difference of −12.6 %-points (95% confidence interval, −15.3 to −9.8; P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo (82.2% versus 53.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
American Gastroenterological Association 2022 guideline: recommendations for semaglutide 2.4 mg and liraglutide 3.0 mg
“The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
American Diabetes Association 2026 Standards of Care: preferred incretin pharmacotherapy and continuation
“In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide), especially considering their added weight-independent benefits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obesity pharmacotherapy indicated for chronic therapy should be continued beyond reaching weight loss goals to maintain the health benefits, as discontinuation often results in recurrence of weight gain and worsening or reemergence of cardiometabolic risk factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical trials have shown that sudden discontinuation of semaglutide and tirzepatide results in weight recurrence of one-half to two-thirds of the weight loss within 1 year with reversal of cardiometabolic improvements” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
World Health Organization 2025 guideline: conditional recommendation for long-term GLP-1 therapies
“WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both recommendations were graded conditional, reflecting that GLP-1 therapies-with or without behavioral therapy-are effective, but limited long-term data, cost, system readiness, equity, variability in patient priorities, and context-specific feasibility remain considerations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide injection and tablets: wholesale acquisition cost
| Product and package | Quoted WAC price |
|---|---|
| Tablets, 25 mg, 30 tablets per bottle | “$1,349.02” |
| Injection, 2.4 mg dose, 4-pen package | “$1,349.02” |
| Wegovy HD injection, 7.2 mg dose, 4-pen package | “$1,349.02” |
Semaglutide injection and tablets: list price reduction effective January 2027
Liraglutide and semaglutide: average wholesale price and National Average Drug Acquisition Cost
| Medication | Typical adult maintenance dose | AWP for 30-day supply | NADAC for 30-day supply |
|---|---|---|---|
| Liraglutide | “3 mg daily”View highlighted excerpt for this quote | “$1,619”View highlighted excerpt for this quote | “$1,303”View highlighted excerpt for this quote |
| Semaglutide | “2.4 mg once weekly”View highlighted excerpt for this quote | “$1,619”View highlighted excerpt for this quote | “$1,302”View highlighted excerpt for this quote |